Johnson & Johnson Posts Sales Increase in 1Q 2019

By Staff
Wednesday, April 17, 2019 12:21 AM NEW BRUNSWICK, N.J.—Johnson & Johnson (NYSE: JNJ) reported sales of $20.02 billion for the first quarter ended March 31, 2019, reflecting growth of 0.1 percent, operational growth of 3.9 percent and adjusted operational growth of 5.5 percent increase. The increases were driven in part by strong sales of Acuvue contact lenses by its vision business, J&J said. The health care conglomerate said net profit fell to $3.75 billion from $4.37 billion in the prior year. “Our strong first-quarter results reflect continued underlying operational sales and adjusted earnings per share (EPS) growth,” said Alex Gorsky, chairman and CEO.

NCCVEH at Prevent Blindness Names First Partners in ‘Better Vision Together-Community of Practice’ Program

By Staff
Wednesday, April 17, 2019 12:18 AM CHICAGO—The National Center for Children’s Vision and Eye Health at Prevent Blindness (NCCVEH) has announced the first partners of its “Better Vision Together-Community of Practice” program. According to a release, the goal of this project is to improve vision and eye health in at-risk, minority and vulnerable populations of young children. The NCCVEH will work with selected groups to provide aid and solutions that are rooted in population health strategies through a peer-support approach. These include policy change, systems of vision and eye health, public awareness, and data collection.

RightEye Offers Researchers a Database to Track Neurological Conditions

By Staff
Wednesday, April 3, 2019 12:15 AM BETHESDA, Md.—RightEye announced that it has built an extensive database that is being used by major research and health institutions to examine the eye-brain connection and detect the early onset of neurological conditions such as Parkinson’s Disease. The database was built using more than one billion data points from over 100,000 patient tests conducted with RightEye’s eye-tracking system. The anonymized data, which RightEye expects to exceed two billion data points by year end, is providing researchers with a new and deeper understanding of early indicators for neurological issues, which are anticipated to help in the development of new treatment options and interventions, the company said.

RightEye Offers Researchers a Database to Track Neurological Conditions

By Staff
Tuesday, April 2, 2019 9:00 AM BETHESDA, Md.—RightEye announced that it has built an extensive database that is being used by major research and health institutions to examine the eye-brain connection and detect the early onset of neurological conditions such as Parkinson’s Disease. The database was built using more than one billion data points from over 100,000 patient tests conducted with RightEye’s eye-tracking system. The anonymized data, which RightEye expects to exceed two billion data points by year end, is providing researchers with a new and deeper understanding of early indicators for neurological issues, which are anticipated to help in the development of new treatment options and interventions, the company said.

New Research Projects Larger Dramatic Rise in Myopia Among Children Around the World at First Sightgeist Conference

By Staff
Tuesday, April 2, 2019 12:24 AM LONDON—Clearly, a global charity tackling the issue of poor vision has highlighted the dramatic rise of myopia among children around the world, with figures set to increase from an already worrying 300 million children today to 500 million by 2050. The revised data was featured at the start of Sightgeist a one-day event held here set up by Clearly founder James Chen on March 28, uniting many stakeholders and organizations working to address unmet vision care access around the world.

Alcon Acquires IOL Lens Development Company PowerVision Inc.

By Staff
Tuesday, March 19, 2019 12:30 AM FORT WORTH, Texas—Alcon, a global leader in eyecare, said Monday it has acquired PowerVision Inc., a privately-held, U.S.-based medical device development company focused on creating fluid-based intraocular lens implants. Alcon said the acquisition furthers its commitment to drive growth and innovation in advanced technology intraocular lenses (AT-IOLS) to meet the needs of cataract surgery patients who desire spectacle independence. “As the industry leader in cataract surgery, we’re eager to accelerate development of this potentially breakthrough accommodating lens technology,” said Alcon’s Michael Onuscheck, president of global business and innovation.

California Optometric Association Helps Diabetes Patients Connect With Health Care

By Staff
Wednesday, February 20, 2019 12:15 AM SACRAMENTO, Calif.—A recent California Health Policy Strategies policy brief finds that the partnership between the California Optometric Association (COA), Anthem Blue Cross Medi-Cal Health Plan, and community health centers throughout California was successful in connecting diabetes patients with comprehensive care. In this partnership, Anthem Blue Cross Medi-Cal Health Plan reached out to its members with a history of diabetes who had not accessed recommended health screenings, and invited them to the Diabetes Day Clinic at a local health center.

Janssen Enters Collaboration Agreement With MeiraGTx to Develop Programs for Inherited Retinal Diseases

By Staff
Tuesday, February 12, 2019 12:15 AM RARITAN, N.J.—The Janssen unit of Johnson & Johnson has announced a worldwide collaboration and license agreement with MeiraGTx Holdings (NASDAQ:MGTX), a clinical-stage gene therapy company, to develop, manufacture and commercialize its clinical stage inherited retinal disease portfolio. The portfolio includes leading product candidates for achromatopsia (ACHM) caused by mutations in either CNGB3 or CNGA3, and X-linked retinitis pigmentosa (XLRP). Further, the companies have formed a research collaboration to explore new targets for other inherited retinal diseases and further develop adeno-associated virus (AAV) manufacturing technology, according to an announcement.

MEGATREND: Screen Time

By Andrew Karp
Monday, January 21, 2019 12:30 AM As recently as a decade ago, a mention of digital eye strain (DES) would have most people scratching their heads. Today it’s ubiquitous, a condition of modern life. From toddlers to millennials to seniors, from city dwellers to shepherds in remote mountain villages, no one is immune from DES and its effects, which include dry, irritated eyes, blurred vision and assorted aches and pains. More than half of American adults suffer adverse effects from overexposure to screens, according to The Vision Council, which coined the term digital eye strain.

Lens Solutions for Digital Eye Strain

By Andrew Karp
Monday, January 21, 2019 12:29 AM As knowledge and awareness of digital eye strain has increased, so too have the number of solutions for alleviating its symptoms. Solutions range from behavioral—reducing screen time, adjusting work spaces, work habits and screen brightness—to a growing range of products designed to prevent or alleviate DES symptoms.

Raising Awareness of DES

By Andrew Karp
Monday, January 21, 2019 12:28 AM As part of its ongoing efforts to raise public awareness of digital eyestrain, The Vision Council conducted a media campaign in 2018 in conjunction with Health Vision Month in May. The Vision Council teamed up with actress, journalist, podcaster and TV host Maria Menounos—best known for her correspondence on “E! News”—for a sponsored Instagram post promoting the importance of wearing glasses outfitted with specialized lenses to protect the eyes from digital devices, highlighting product from Eyewear & Accessories (E&A) Division member Marchon Eyewear. Menounos reaches 971,000 followers on Instagram, and her post has received nearly 14,000 likes.

Digital Eye Strain and Myopia

By Andrew Karp
Monday, January 21, 2019 12:27 AM Many vision researchers believe there is growing evidence that digital screen use is a contributing factor to the spread of myopia worldwide. For example, Essilor USA’s website, Myopiaexperts (https://www.essilorusa.com/myopiaexperts#/), points out that myopia tends to progress during childhood, as the eyes continue to grow and develop.

49 Ways to Balance the Blues

By Andrew Karp
Monday, January 21, 2019 12:26 AM Exposure to blue light between 410 and 450 nm contributes to digital eye strain. Vision Monday has compiled an online resource that consists of descriptions of 48 different products that offer blue light management solutions for every situation, both indoors and outdoors.

SightGlass Vision Clinical Trial to Control Childhood Nearsightedness Is Now Enrolling Patients

By Staff
Tuesday, January 15, 2019 12:18 AM PALO ALTO, Calif.—SightGlass Vision, Inc. has announced that CYPRESS, a clinical trial to control nearsightedness in children, is now enrolling patients in the U.S. and Canada. This CYPRESS study will evaluate the safety and efficacy of SightGlass Vision’s novel lenses compared to standard lenses to reduce the rate of progression of myopia in children between the ages of six and nine over the course of 36 months. The multicenter, double-blinded, randomized controlled trial will enroll 255 patients across 14 sites in the U.S. and Canada. SightGlass expects to complete trial enrollment by the end of Q1 2019, and to report their initial results in 2020, which will later be accompanied by additional data after a longer-term follow up.

Vision Insurance Is Differentiator to Millennials in Job Search

By Staff
Friday, January 4, 2019 12:15 AM BALTIMORE—A national employee benefits provider finds that cutting vision health insurance benefits may prompt up to one-third of working Millennials to look for a new job. According to an online survey conducted by Unum of more than 1,200 people working in the U.S., 34 percent of people aged 25 to 34 consider vision insurance to be a key factor when choosing (or leaving) an employer.